KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.90), $0.16 better than the analyst estimate of ($1.06).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'